A team of Montana researchers is playing a key role in the development of a more effective vaccine against tuberculosis, an infectious disease that has killed more people than any other.
This story also ran on U.S. News & World Report. It can be republished for free.
The BCG (Bacille Calmette-Gurin) vaccine, created in 1921, remains the sole TB vaccine. While it is 40% to 80% effective in young children, its efficacy is very low in adolescents and adults, leading to a worldwide push to create a more powerful vaccine.
One effort is underway at the University of Montana Center for Translational Medicine. The center specializes in improving and creating vaccines by adding what are called novel adjuvants. An adjuvant is a substance included in the vaccine, such as fat molecules or aluminum salts, that enhances the immune response, and novel adjuvants are those that have not yet been used in humans. Scientists are finding that adjuvants make for stronger, more precise, and more durable immunity than antigens, which create antibodies, would alone.
Eliciting specific responses from the immune system and deepening and broadening the response with adjuvants is known as precision vaccination. Its not one-size-fits-all, said Ofer Levy, a professor of pediatrics at Harvard University and the head of the Precision Vaccines Program at Boston Childrens Hospital. A vaccine might work differently in a newborn versus an older adult and a middle-aged person.
The ultimate precision vaccine, said Levy, would be lifelong protection from a disease with one jab. A single-shot protection against influenza or a single-shot protection against covid, that would be the holy grail, Levy said. Email Sign-Up
Subscribe to KFF Health News' free Morning Briefing. Your Email Address Sign Up
Jay Evans, the director of the University of Montana center and the chief scientific and strategy officer and a co-founder of Inimmune, a privately held biotechnology company in Missoula, said his team has been working on a TB vaccine for 15 years. The private-public partnership is developing vaccines and trying to improve existing vaccines, and he said its still five years off before the TB vaccine might be distributed widely.
It has not gone unnoticed at the center that this state-of-the-art vaccine research and production is located in a state that passed one of the nations most extreme anti-vaccination laws during the pandemic in 2021. The law prohibits businesses and governments from discriminating against people who arent vaccinated against covid-19 or other diseases, effectively banning both public and private employers from requiring workers to get vaccinated against covid or any other disease. A federal judge later ruled that the law cannot be enforced in health care settings, such as hospitals and doctors offices.
In mid-March, the Bill & Melinda Gates Medical Research Institute announced it had begun the third and final phase of clinical trials for the new vaccine in seven countries. The trials should take about five years to complete. Research and production are being done in several places, including at a manufacturing facility in Hamilton owned by GSK, a giant pharmaceutical company.
Known as the forgotten pandemic, TB kills up to 1.6 million people a year, mostly in impoverished areas in Asia and Africa, despite its being both preventable and treatable. The U.S. has seen an increase in tuberculosis over the past decade, especially with the influx of migrants, and the number of cases rose by 16% from 2022 to 2023. Tuberculosis is the leading cause of death among people living with HIV, whose risk of contracting a TB infection is 20 times as great as people without HIV.
TB is a complex pathogen that has been with human beings for ages, said Alemnew Dagnew, who heads the program for the new vaccine for the Gates Medical Research Institute. Because it has been with human beings for many years, it has evolved and has a mechanism to escape the immune system. And the immunology of TB is not fully understood.
The University of Montana Center for Translational Medicine and Inimmune together have 80 employees who specialize in researching a range of adjuvants to understand the specifics of immune responses to different substances. You have to tailor it like tools in a toolbox towards the pathogen you are vaccinating against, Evans said. We have a whole library of adjuvant molecules and formulations.
Vaccines are made more precise largely by using adjuvants. There are three basic types of natural adjuvants: aluminum salts; squalene, which is made from shark liver; and some kinds of saponins, which are fat molecules. Its not fully understood how they stimulate the immune system. The center in Missoula has also created and patented a synthetic adjuvant, UM-1098, that drives a specific type of immune response and will be added to new vaccines.
One of the most promising molecules being used to juice up the immune system response to vaccines is a saponin molecule from the bark of the quillay tree, gathered in Chile from trees at least 10 years old. Such molecules were used by Novavax in its covid vaccine and by GSK in its widely used shingles vaccine, Shingrix. These molecules are also a key component in the new tuberculosis vaccine, known as the M72 vaccine. More from the Mountain States
But there is room for improvement.
The vaccine shows 50% efficacy, which doesnt sound like much, but basically there is no effective vaccine currently, so 50% is better than whats out there, Evans said. Were looking to take what we learned from that vaccine development with additional adjuvants to try and make it even better and move 50% to 80% or more.
By contrast, measles vaccines are 95% effective.
According to Medscape, around 15 vaccine candidates are being developed to replace the BCG vaccine, and three of them are in phase 3 clinical trials.
One approach Evans center is researching to improve the new vaccines efficacy is taking a piece of the bacterium that causes TB, synthesizing it, and combining it with the adjuvant QS-21, made from the quillay tree. It stimulates the immune system in a way that is specific to TB and it drives an immune response that is even closer to what we get from natural infections, Evans said.
The University of Montana center is researching the treatment of several problems not commonly thought of as treatable with vaccines. They are entering the first phase of clinical trials for a vaccine for allergies, for instance, and first-phase trials for a cancer vaccine. And later this year, clinical trials will begin for vaccines to block the effects of opioids like heroin and fentanyl. The University of Montana received the largest grant in its history, $33 million, for anti-opioid vaccine research. It works by creating an antibody that binds with the drug in the bloodstream, which keeps it from entering the brain and creating the high.
For now, though, the eyes of health care experts around the world are on the trials for the new TB vaccines, which, if they are successful, could help save countless lives in the worlds poorest places. Related Topics Pharmaceuticals Public Health States Children's Health Montana Vaccines Contact Us Submit a Story Tip
A British fintech which counts Standard Life among its key clients is close to finalising one of the industry’s biggest funding rounds so far this year.
Sky News understands that Hyperlayer, which is run by the former Morgan Stanley executive Rob Rooney, is lining up a major equity injection led by CDAM, a UK-based investment firm, and several new institutional investors.
City sources said this weekend that the new capital from CDAM and other backers could total at least £30m.
The funding round is expected to take place at a post-money valuation of about £160m.
Hyperlayer, which operates a consumer-facing digital wallet called Hyperjar, intends to use the new funding as growth capital to finance the development of new partnerships with global banks and asset managers.
The company provides smart account technology on existing client infrastructure, and is said to work with a number of the world’s 10 largest banks – although it has not publicly disclosed their identities.
Its work with Standard Life involves the future launch of a consumer money app aimed at people approaching or in early retirement.
Hyperlayer’s consumer-facing platform sees customers organise their money in what the company calls “digital jam jars”, enabling them to earn rewards which give them access to partner brands such as Asda, Morrisons and Starbucks.
IKEA and the John Lewis Partnership are among the other merchant partners with which Hyperlayer is working to develop distinctive loyalty-based initiatives for its financial institution clients.
Founded in 2006 by Adam Chamberlain and Scott Davies, CDAM has $1.5bn in assets under management and is an experienced investor in financial services technology.
Mr Davies has had a seat on Hyperlayer’s board for several years.
Mr Rooney, who was a prominent Wall Street executive for years, ultimately serving as Morgan Stanley’s technology operations, joined the company as CEO in 2023.
The new capital injection led by CDAM is understood to be subject to approval by Hyperlayer’s shareholders.
Thoroughbred racing suffered its most ignominious, industry-deflating moment 50 years ago today with the breakdown of Ruffian, an undefeated filly running against Foolish Pleasure in a highly promoted match race at Belmont Park. Her tragic end on July 6, 1975, was a catastrophe for the sport, and observers say racing has never truly recovered.
Two years earlier, during the rise of second-wave feminism, the nation had been mesmerized by a “Battle of the Sexes” tennis match between Billie Jean King and Bobby Riggs. King’s win became a rallying cry for women everywhere. The New York Racing Association, eager to boost daily racing crowds in the mid-1970s, proposed a competition similar to that of King and Riggs. They created a match race between Kentucky Derby winner Foolish Pleasure and Ruffian, the undefeated filly who had dominated all 10 of her starts, leading gate to wire.
“In any sport, human or equine, it’s really impossible to say who was the greatest,” said outgoing Jockey Club chairman Stuart Janney III, whose parents, Stuart and Barbara, owned Ruffian. “But I’m always comfortable thinking of Ruffian as being among the four to five greatest horses of all time.”
Ruffian, nearly jet black in color and massive, was the equine version of a Greek goddess. At the age of 2, her girth — the measurement of the strap that secures the saddle — was just over 75 inches. Comparatively, racing legend Secretariat, a male, had a 76-inch girth when he was fully developed at the age of 4.
Her name also added to the aura. “‘Ruffian’ was a little bit of a stretch because it tended to be what you’d name a colt, but it turned out to be an appropriate name,” Janney said.
On May 22, 1974, Ruffian equaled a Belmont Park track record, set by a male, in her debut at age 2, winning by 15 lengths. She set a stakes record later that summer at Saratoga in the Spinaway, the most prestigious race of the year for 2-year-old fillies. The next spring, she blew through races at longer distances, including the three races that made up the so-called Filly Triple Crown.
Some in the media speculated that she had run out of female competition.
Foolish Pleasure had meanwhile ripped through an undefeated 2-year-old season with championship year-end honors. However, after starting his sophomore campaign with a win, he finished third in the Florida Derby. He also had recovered from injuries to his front feet to win the Wood Memorial and then the Kentucky Derby.
Second-place finishes in the Preakness and Belmont Stakes left most observers with the idea that Foolish Pleasure was the best 3-year-old male in the business.
Following the Belmont Stakes, New York officials wanted to test the best filly against the best colt.
The original thought was to include the Preakness winner, Master Derby, in the Great Match Race, but the team of Foolish Pleasure’s owner, trainer and rider didn’t want a three-horse race. Since New York racing had guaranteed $50,000 to the last-place horse, they paid Master Derby’s connections $50,000 not to race. Thus, the stage was set for an equine morality play.
“[Ruffian’s] abilities gave her the advantage in the match race,” Janney said. “If she could do what she did in full fields [by getting the early lead], then it was probably going to be even more effective in a match.”
Several ballyhooed match races in sports history had captured the world’s attention without incident — Seabiscuit vs. Triple Crown winner War Admiral in 1938, Alsab vs. Triple Crown winner Whirlaway in 1942, and Nashua vs. Swaps in 1955. None of those races, though, had the gender divide “it” factor.
The Great Match Race attracted 50,000 live attendees and more than 18 million TV viewers on CBS, comparable to the Grammy Awards and a pair of NFL “Sunday Night Football” games in 2024.
Prominent New York sportswriter Dick Young wrote at the time that, for women, “Ruffian was a way of getting even.”
“I can remember driving up the New Jersey Turnpike, and the lady that took the toll in one of those booths was wearing a button that said, ‘I’m for her,’ meaning Ruffian,” Janney said.
As the day approached, Ruffian’s rider, Jacinto Vasquez, who also was the regular rider of Foolish Pleasure including at the Kentucky Derby, had to choose whom to ride for the match race.
“I had ridden Foolish Pleasure, and I knew what he could do,” Vasquez told ESPN. “But I didn’t think he could beat the filly. He didn’t have the speed or stamina.”
Braulio Baeza, who had ridden Foolish Pleasure to victory in the previous year’s premier 2-year-old race, Hopeful Stakes, was chosen to ride Foolish Pleasure.
“I had ridden Foolish Pleasure and ridden against Ruffian,” Baeza said, with language assistance from his wife, Janice Blake. “I thought Foolish Pleasure was better than Ruffian. She just needed [early race] pressure because no one had ever pressured her.”
The 1⅛ mile race began at the start of the Belmont Park backstretch in the chute. In an ESPN documentary from 2000, Jack Whitaker, who hosted the race telecast for CBS, noted that the atmosphere turned eerie with dark thunderclouds approaching before the race.
Ruffian hit the side of the gate when the doors opened but straightened herself out quickly and assumed the lead. “The whole world, including me, thought that Ruffian was going to run off the screen and add to her legacy,” said longtime New York trainer Gary Contessa, who was a teenager when Ruffian ruled the racing world.
However, about ⅛ of a mile into the race, the force of Ruffian’s mighty strides snapped two bones in her front right leg.
“When she broke her leg, it sounded like a broken stick,” Vasquez said. “She broke her leg between her foot and her ankle. When I pulled up, the bone was shattered above the ankle. She couldn’t use that leg at all.”
It took Ruffian a few moments to realize what had happened to her, so she continued to run. Vasquez eventually hopped off and kept his shoulder leaning against her for support.
“You see it, but you don’t want to believe it,” Janney said.
Baeza had no choice but to have Foolish Pleasure finish the race in what became a macabre paid workout. The TV cameras followed him, but the eyes of everyone at the track were on the filly, who looked frightened as she was taken back to the barn area.
“When Ruffian broke down, time stood still that day,” Contessa said. Yet time was of the essence in an attempt to save her life.
Janney said that Dr. Frank Stinchfield — who was the doctor for the New York Yankees then and was “ahead of his time in fixing people’s bones” — called racing officials to see whether there was anything he could do to help with Ruffian.
New York veterinarian Dr. Manny Gilman managed to sedate Ruffian, performed surgery on her leg and, with Stinchfield’s help, secured her leg in an inflatable cast. When Ruffian woke up in the middle of the night, though, she started fighting and shattered her bones irreparably. Her team had no choice but to euthanize her at approximately 2:20 a.m. on July 7.
“She was going full bore trying to get in front of [Foolish Pleasure] out of the gate,” Baeza said. “She gave everything there. She gave her life.”
Contessa described the time after as a “stilled hush over the world.”
“When we got the word that she had rebroken her leg, the whole world was crying,” Contessa said. “I can’t reproduce the feeling that I had the day after.”
The Janneys soon flew to Maine for the summer, and they received a round of applause when the pilot announced their presence. At the cottage, they were met by thousands of well-wishing letters.
“We all sat there, after dinner every night, and we wrote every one of them back,” Janney said. “It was pretty overwhelming, and that didn’t stop for a long time. I still get letters.”
Equine fatalities have been part of the business since its inception, like the Triple Crown races and Breeders’ Cup. Some have generated headlines by coming in clusters, such as Santa Anita in 2019 and Churchill Downs in 2023. However, breakdowns are not the only factor, and likely not the most influential one, in the gradual decline of horse racing’s popularity in this country.
But the impact from the day of Ruffian’s death, and that moment, has been ongoing for horse racing.
“There are people who witnessed the breakdown and never came back,” Contessa said.
Said Janney: “At about that time, racing started to disappear from the national consciousness. The average person knows about the Kentucky Derby, and that’s about it.”
Equine racing today is a safer sport now than it was 50 years ago. The Equine Injury Database, launched by the Jockey Club in 2008, says the fatality rate nationally in 2024 was just over half of what it was at its launch.
“We finally have protocols that probably should have been in effect far sooner than this,” Contessa said. “But the protocols have made this a safer game.”
Said Vasquez: “There are a lot of nice horses today, but to have a horse like Ruffian, it’s unbelievable. Nobody could compare to Ruffian.”
The UK has re-established diplomatic ties with Syria, David Lammy has said, as he made the first visit to the country by a British minister for 14 years.
The foreign secretary visited Damascus and met with interim president Ahmed al Sharaa, also the leader of the rebel group Hayat Tahrir al-Sham (HTS), and foreign minister Asaad al Shaibani.
In a statement, Mr Lammy said a “stable Syria is in the UK’s interests” and added: “I’ve seen first-hand the remarkable progress Syrians have made in rebuilding their lives and their country.
“After over a decade of conflict, there is renewed hope for the Syrian people.
“The UK is re-establishing diplomatic relations because it is in our interests to support the new government to deliver their commitment to build a stable, more secure and prosperous future for all Syrians.”
Image: Foreign Secretary David Lammy with Syria’s interim president Ahmed al Sharaa in Damascus. Pic: X / @DavidLammy
The Foreign, Commonwealth and Development Office has also announced a £94.5m support package for urgent humanitarian aid and to support the country’s long-term recovery, after a number of British sanctions against the country were lifted in April.
While HTS is still classified as a proscribed terror group, Sir Keir Starmer said last year that it could be removed from the list.
The Syrian president’s office also said on Saturday that the president and Mr Lammy discussed co-operation, as well as the latest developments in the Middle East.
Since Assad fled Syria in December, a transitional government headed by Mr al Sharaa was announced in March and a number of western countries have restored ties.
In May, US President Donald Trump said the United States would lift long-standing sanctions on Syria and normalise relations during a speech at the US-Saudi investment conference.
Please use Chrome browser for a more accessible video player
1:12
From May: Trump says US will end sanctions for Syria
He said he wanted to give the country “a chance at peace” and added: “There is a new government that will hopefully succeed.
“I say good luck, Syria. Show us something special.”
